Navigation Links
Kidney stenting lowers blood pressure in patients with severe hypertension
Date:8/30/2012

Patients with uncontrolled renovascular hypertension saw a significant improvement in their blood pressure with renal artery stent deployment. The multicenter HERCULES trial, evaluating the safety and effectiveness of the RX Herculink Elite Stent, found that patients with higher blood pressure levels at baseline had the most dramatic reduction in blood pressure following intervention. Trial details appear in Catheterization and Cardiovascular Interventions, a journal published by Wiley on behalf of the Society for Cardiovascular Angiography and Interventions (SCAI).

Narrowing of the arteries to the kidney known as renal artery stenosis (RAS) is mainly caused by the build-up of fat and cholesterol (atherosclerosis) along the artery walls. The plaque build-up can cause high blood pressure and kidney damage. While kidney artery stenting is considered a safe procedure, the efficacy of the procedure for lowering blood pressure and preventing injury that leads to end-stage renal disease remains unclear, particularly when compared to medicines alone.

"Findings from the HERCULES trial expand scientific evidence of renal artery stenting in treating patients with high blood pressure who do not respond to standard therapy," explains Michael R. Jaff, DO, FSCAI, from the Vascular Center at Massachusetts General Hospital in Boston. "As part of the trial we also explored the predictive value of the brain natriuretic peptide (BNP) test prior to performing the stent procedure." The BNP test is used to diagnose heart failure and researchers sought to understand if BNP could predict clinical success, which is valuable information for interventionists prior to performing invasive procedures.

For the HERCULES trial researchers enrolled 202 patients with 241 total lesions and 78 bilateral lesions between August 2007 and October 2009. Patients had a history of high cholesterol levels and active or recently discontinued tobacco use. The majority of participants were Caucasian, mean age was 72 years, and 62% of patients were female. BNP testing was performed before and after stenting with the RX Herculink Elite Renal Stent System by Abbott Vascular.

At the start of the trial the mean systolic blood pressure of the trial group was 162 mm Hg and nearly 70% of patients were taking three or more medications to control hypertension. Success rates for the trial device, procedure and clinical outcomes were 96%, 99%, and 98%, respectively. Researchers reported that freedom from major adverse events (death, kidney removal, or embolism causing renal injury) was 95%.

Further results show that at the nine-month follow-up the restenosis rate was 11% and the mean systolic blood pressure for participants was 145 mm Hg post-stenting with no change in medications. Researchers found no association between a reduction in blood pressure following stenting and elevated BNP pre-procedure, or a decrease in BNP levels following successful stenting. While there was a significant decrease in BNP following stenting, the BNP level prior to the procedure was not reliable in predicting blood pressure response.

"The HERCULES trial demonstrates that renal artery stent revascularization significantly lowers systolic blood pressure in patients with severe hypertension," concludes Dr. Jaff. "Those patients with the highest blood pressure rates at baseline had the greatest magnitude of blood pressure lowering." The authors point out that because the majority of trial participants were Caucasian the findings may not be applicable to other racial groups.

In a related video, Dr. Jaff discusses specifics of his research with Steven R. Bailey, MD, FSCAI, Editor-in-Chief of Catheterization and Cardiovascular Interventions. "The research by Dr. Jaff and colleagues is an important contribution to the evidence supporting stenting as an effective intervention for patients with renovascular disease," said Dr. Bailey.


'/>"/>

Contact: Dawn Peters
sciencenewsroom@wiley.com
781-388-8408
Wiley
Source:Eurekalert

Related medicine news :

1. Not Enough Data to Support Kidney Disease Screening, Task Force Says
2. New insights into salt transport in the kidney
3. Men Have a Greater Lifetime Risk for Kidney Failure: Study
4. Drinking Iced Tea Raises Kidney Stone Risk: Study
5. Mayo Clinic: Drug duo turns on cancer-fighting gene in kidney, breast cancers
6. Moderate alcohol intake is associated with a lower risk of kidney cancer
7. Blood condition is highly predictive of graft failure in pediatric kidney transplant
8. AACR and Kure It partner to offer a new grant for kidney cancer research
9. Protecting the hearts of those waiting for kidney and liver transplants
10. U-M researchers identify new genetic cause for chronic kidney disease
11. Vanderbilt study finds obesity linked to kidney injury after heart surgery
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... ... February 23, 2017 , ... ERT, a global ... announced that Premier Research, a leading clinical development service provider, has selected ERT’s ... increasingly complex, due in part to an array of circumstances including the use ...
(Date:2/23/2017)... ... (PRWEB) February 23, 2017 ... nation to come together to combine its favorite springtime pastime ... favorite fruit – apples! To celebrate National Nutrition Month, the ... “Apple Madness” bracket tournament – a five-week, five-round online competition ...
(Date:2/23/2017)... , ... February 23, 2017 , ... HealthPostures, the desk ... an expert sit stand solutions representative to the Minneapolis Home and Garden Show which ... the event that is garnering national attention is the Minneapolis Convention Center. , ...
(Date:2/22/2017)... York, NY (PRWEB) , ... February 22, 2017 ... ... professional life and athletics. It’s enough to overwork even the sharpest brain. , ... that offer peak healthy activity without over clocking the brain. Each capsule contains ...
(Date:2/22/2017)... ... February 22, 2017 , ... Secure Exchange Solutions, ... largest network of hospitals, health information exchanges, physicians and patients, announced today that ... (ONC-HIT) 2015 Edition Health IT Module Certification via Drummond Group LLC, an Authorized ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... Tillotts Pharma is strengthening its presence in ... office was opened in January 2017 under the management ... ® for the treatment of Crohn,s disease, Asacol ... VistaPrep ® for bowel preparation before endoscopy. With ... on the treatment of gastrointestinal (GI) diseases will expand ...
(Date:2/23/2017)... 23, 2017 The U.S. cannabis market ... for recreational use in 2016. According to a new report ... worth an estimated $7.2 billion in 2016 and is projected ... While adult recreational sales are projected to jump from $2.6 ... 25% CAGR. The market may grow faster as the estimate ...
(Date:2/23/2017)... , Feb. 22, 2017 Orthopedic ... implant demand, as aging demographic patterns lead to ... Implants for sports- and exercise-related injuries, chronic back ... will lead sales gains. The future of medical ... addresses the following questions and more: - ...
Breaking Medicine Technology: